Altre lingue Outlook Therapeutics, Inc.

Azioni

OTLK

US69012T3059

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
8,6 ^USD	+1,18%		+2,02%	+9,14%

27/03	Le azioni di Outlook Therapeutics aumentano dopo l'aggiornamento di BTIG	MT
27/03	OUTLOOK THERAPEUTICS, INC. : BTIG da Neutral a Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Outlook Therapeutics® to Present at the Retina World Congress 2024	02/05
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	15/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Corporate Presentation: March 2024	28/03
North American Morning Briefing : Stocks Set for -2-	28/03
Outlook Therapeutics Shares Rise After BTIG Upgrade	27/03
Outlook Therapeutics Reports Secondary Share Offering	25/03
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	25/03
Sector Update: Health Care Stocks Ease Late Afternoon	22/03
Sector Update: Health Care Stocks Ease Friday Afternoon	22/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22/03
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	22/03
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	19/03
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab	19/03
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	18/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Outlook Therapeutics, Inc.

Azioni

OTLK

US69012T3059

Altre lingue

Filtri